SCHEMBL16614239

SCHEMBL16614239

CCOC(=O)c1cccc(Sc2c(C)n(CC(=O)NCC(F)(F)F)c3c(F)c(Cl)ccc23)c1

nearest known ligand 0.76

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 19/20 0.76
AKR1B1 P15121 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16600443 0.90 ENPP2 (0.62) ENPP2AKR1B1PTGDR2
SCHEMBL16600487 0.90 ENPP2 (0.68) ENPP2AKR1B1PTGDR2
SCHEMBL16600432 0.88 ENPP2 (0.79) ENPP2AKR1B1PTGDR2
SCHEMBL16600467 0.87 ENPP2 (0.80) ENPP2AKR1B1PTGDR2
SCHEMBL16600570 0.86 ENPP2 (1.00) ENPP2
SCHEMBL16614206 0.86 ENPP2 (0.87) ENPP2AKR1B1PTGDR2
SCHEMBL16600656 0.85 ENPP2 (0.86) ENPP2AKR1B1PTGDR2
SCHEMBL17940586 0.85 ENPP2 (0.72) ENPP2AKR1B1PTGDR2
SCHEMBL16600385 0.84 ENPP2 (0.76) ENPP2
SCHEMBL16601011 0.84 ENPP2 (1.00) ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9850203-B2 Autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2017-12-26 US disclosed
US-9850203-B2 Autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2017-12-26 US disclosed
US-20160214935-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-07-28 US disclosed
US-20160214935-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-07-28 US disclosed
WO-2015048301-A1 AUTOTAXIN INHIBITOR COMPOUNDS PHARMAKEA, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214935-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINE1 ENPP2 1/4885AKR1B1 3956/4885PTGDR2 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.